Human cells with a 'built-in circuit' help prevent tumour growth

Human cells with a ‘built-in circuit’ help prevent tumour growth
The attached image shows microscope images of the engineered cells (nuclei in blue) with HIF-1 visualized (in red). In the left hand panel, cells are in hypoxia but no doxyxyclin is present, therefore HIF-1 remains active (red dots). In the right hand panel, the cells are grown in hypoxia and in the presence of doxyxyxlin, therefore the cyclic peptide inhibitor is produced and HIF-1 is inhibited, as demonstrated by the absence of the red dots. Credit: University of Southampton

Researchers at the University of Southampton have engineered cells with a 'built-in genetic circuit' that produces a molecule that inhibits the ability of tumours to survive and grow in their low oxygen environment.

The genetic circuit produces the machinery necessary for the production of a compound that inhibits a protein which has a significant and critical role in the growth and survival of . This results in the cancer cells being unable to survive in the low oxygen, low nutrient tumour micro-environment.

As tumours develop and grow, they rapidly outstrip the supply of oxygen delivered by existing blood vessels. This results in cancer cells needing to adapt to low oxygen environment.

To enable them to survive, adapt and grow in the low-oxygen or 'hypoxic' environments, tumours contain increased levels of a protein called Hypoxia-inducible factor 1 (HIF-1). HIF-1 senses reduced oxygen levels and triggers many changes in cellular function, including a changed metabolism and sending signals for the formation of new . It is thought that tumours primarily hijack the function of this protein (HIF-1) to survival and grow.

Professor Ali Tavassoli, who led the study with colleague Dr. Ishna Mistry, explains: "In an effort to better understand the role of HIF-1 in cancer, and to demonstrate the potential for inhibiting this protein in cancer therapy, we engineered a human cell line with an additional genetic circuit that produces the HIF-1 inhibiting molecule when placed in a hypoxic environment.

"We've been able to show that the engineered cells produce the HIF-1 inhibitor, and this molecule goes on to inhibit HIF-1 function in cells, limiting the ability of these cells to survive and grow in a nutrient-limited environment as expected.

"In a wider sense, we have given these engineered cells the ability to fight back – to stop a key protein from functioning in cancer cells. This opens up the possibility for the production and use of sentinel circuits, which produce other bioactive compounds in response to environmental or cellular changes, to target a range of diseases including cancer."

The is incorporated onto the chromosome of a human cell line, which encodes the protein machinery required for the production of their cyclic peptide HIF-1 inhibitor. The production of the HIF-1 inhibitor occurs in response to hypoxia in these cells. The research team demonstrated that even when produced directly in cells, this molecule still prevents the HIF-1 signalling and the associated adaptation to hypoxia in these cells.

The next step for the researchers is to demonstrate the viability of this approach to the production and delivery of an anticancer molecule in a whole tumour model system.

Professor Tavassoli adds: "The main application for this work is that it eliminates the need for the synthesis of our inhibitor, so that biologists conducting research into HIF function can easily access our molecule and hopefully discover more about the role of HIF-1 in cancer. This will also let us understand whether inhibiting HIF-1 function alone is enough to block cancer growth in relevant models. Another interesting aspect to the work is that it demonstrates the possibility of adding new machinery to to enable them to make therapeutic agents in response to disease signals."

The study, which was funded by Cancer Research UK and the Engineering and Physical Sciences Research Council, is published in the journal ACS Synthetic Biology.

Explore further

A protein makes the difference

More information: Ishna N. Mistry et al. Reprogramming the Transcriptional Response to Hypoxia with a Chromosomally Encoded Cyclic Peptide HIF-1 Inhibitor, ACS Synthetic Biology (2016). DOI: 10.1021/acssynbio.6b00219
Journal information: ACS Synthetic Biology

Citation: Human cells with a 'built-in circuit' help prevent tumour growth (2016, November 24) retrieved 27 May 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors